The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Eli Lilly rose 3.3% after the drugmaker showed how demand for ... and the Nasdaq composite rose 99.66 points to 19,791.99. In ...

LONDON/SAN FRANCISCO ... are worried whether it will be good enough to retake the lead from rival Eli Lilly (LLY.N), opens new tab in the competitive obesity drug market. In interviews with ...

CHELSEA are set to pay up to £30million for 18-year-old French strike sensation Eli Junior Kroupi. The teenager has hit nine goals in 18 appearances for second-division leaders Lorient and is ...

Schulich Medicine & Dentistry research operations lead Kristy Coleman and professor Dr. Elizabeth Finger (L to R) found intermittent dosing of oxytocin can help improve apathy symptoms in ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.